Ubs Asset Management Americas Inc Xencor Inc Transaction History

Ubs Asset Management Americas Inc

  • $379 Billion
  • Q1 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Xencor Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 180,100 shares of XNCR stock, worth $1.36 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
180,100
Previous 321,308 43.95%
Holding current value
$1.36 Million
Previous $7.38 Million 74.05%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 19, 2025
SELL
$10.64 - $24.13 $1.5 Million - $3.41 Million
-141,208 Reduced 43.95%
180,100 $1.92 Million
Q4 2024

Feb 14, 2025
SELL
$19.43 - $26.84 $224,766 - $310,485
-11,568 Reduced 3.48%
321,308 $7.38 Million
Q3 2024

Nov 14, 2024
SELL
$15.7 - $21.65 $109,586 - $151,117
-6,980 Reduced 2.05%
332,876 $6.69 Million
Q2 2024

Aug 13, 2024
BUY
$18.21 - $24.5 $1.28 Million - $1.72 Million
70,163 Added 26.02%
339,856 $6.43 Million
Q1 2024

May 15, 2024
BUY
$18.65 - $26.52 $6,546 - $9,308
351 Added 0.13%
269,693 $5.97 Million
Q4 2023

Feb 14, 2024
SELL
$16.53 - $21.42 $44,812 - $58,069
-2,711 Reduced 1.0%
269,342 $5.72 Million
Q3 2023

Nov 13, 2023
BUY
$20.08 - $25.39 $84,135 - $106,384
4,190 Added 1.56%
272,053 $5.48 Million
Q1 2023

May 15, 2023
BUY
$25.95 - $36.95 $10,302 - $14,669
397 Added 0.15%
267,863 $7.47 Million
Q4 2022

Feb 14, 2023
BUY
$24.79 - $30.86 $430,676 - $536,130
17,373 Added 6.95%
267,466 $6.96 Million
Q3 2022

Nov 14, 2022
BUY
$24.62 - $32.44 $58,201 - $76,688
2,364 Added 0.95%
250,093 $6.5 Million
Q2 2022

Aug 12, 2022
SELL
$19.74 - $29.01 $351,391 - $516,407
-17,801 Reduced 6.7%
247,729 $6.78 Million
Q1 2022

May 16, 2022
SELL
$26.68 - $41.63 $90,738 - $141,583
-3,401 Reduced 1.26%
265,530 $7.08 Million
Q4 2021

Feb 14, 2022
SELL
$33.67 - $43.44 $221,178 - $285,357
-6,569 Reduced 2.38%
268,931 $10.8 Million
Q3 2021

Nov 15, 2021
SELL
$30.65 - $35.68 $192,972 - $224,641
-6,296 Reduced 2.23%
275,500 $9 Million
Q2 2021

Aug 16, 2021
BUY
$34.33 - $44.68 $2.07 Million - $2.7 Million
60,338 Added 27.25%
281,796 $9.72 Million
Q1 2021

May 14, 2021
SELL
$40.81 - $53.88 $111,533 - $147,254
-2,733 Reduced 1.22%
221,458 $9.54 Million
Q4 2020

Mar 01, 2021
SELL
$36.63 - $47.63 $417,362 - $542,696
-11,394 Reduced 4.84%
224,191 $9.78 Million
Q3 2020

Nov 13, 2020
BUY
$30.09 - $43.02 $221,462 - $316,627
7,360 Added 3.22%
235,585 $9.14 Million
Q2 2020

Aug 14, 2020
BUY
$27.76 - $33.42 $343,946 - $414,073
12,390 Added 5.74%
228,225 $7.39 Million
Q1 2020

May 15, 2020
SELL
$20.69 - $37.79 $609,279 - $1.11 Million
-29,448 Reduced 12.01%
215,835 $6.45 Million
Q4 2019

Feb 14, 2020
BUY
$32.75 - $41.43 $64,779 - $81,948
1,978 Added 0.81%
245,283 $8.44 Million
Q3 2019

Nov 14, 2019
BUY
$33.73 - $46.27 $121,056 - $166,063
3,589 Added 1.5%
243,305 $8.21 Million
Q2 2019

Aug 15, 2019
SELL
$29.6 - $40.93 $83,916 - $116,036
-2,835 Reduced 1.17%
239,716 $0
Q1 2019

May 14, 2019
BUY
$27.85 - $38.09 $1.76 Million - $2.4 Million
63,061 Added 35.13%
242,551 $0
Q4 2018

Feb 13, 2019
BUY
$32.39 - $42.05 $4.74 Million - $6.16 Million
146,385 Added 442.18%
179,490 $6.49 Million
Q2 2018

Aug 14, 2018
BUY
$28.41 - $42.41 $191,369 - $285,673
6,736 Added 25.55%
33,105 $0
Q1 2018

May 14, 2018
BUY
$21.18 - $33.78 $360,060 - $574,260
17,000 Added 181.45%
26,369 $0
Q4 2017

Feb 09, 2018
BUY
$19.29 - $24.83 $180,728 - $232,632
9,369
9,369 $0

Others Institutions Holding XNCR

# of Institutions
211
Shares Held
78.4M
Call Options Held
3.4K
Put Options Held
1.9K
View Full List

About Xencor Inc

XNCR Quotes by TradingView
  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $452M
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email